参考文献/References:
[1] Moayeri A,Mohamadpour M,Mousavi SF,et al.Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis[J].Ther Clin Risk Manag,2017,13:455-468.DOI:10.2147/TCRM.S131945.
[2] Cantini G,Mannucci E,Luconi M.Perspectives in GLP-1 research: new targets, new receptors[J].Trends Endocrinol Metab,2016,27(6):427-438.DOI:10.1016/j.tem.2016.03.017.
[3] Nauck M.Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors[J].Diabetes Obes Metab,2016,18(3):203-216.DOI:10.1111/dom.12591.
[4] Nuche-Berenguer B,Portal-Nún～ez S,Moreno P,et al.Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor[J].J Cell Physiol,2010,225(2):585-592.DOI:10.1002/jcp.22243.
[5] Ma X,Meng J,Jia M,et al.Exendin-4, a glucagon-like peptide-1 receptor agonist, prevents osteopenia by promoting bone formation and suppressing bone resorption in aged ovariectomized rats[J].J Bone Miner Res,2013,28(7):1641-1652.DOI:10.1002/jbmr.1898.
[6] Sun HX,Lu N,Luo X,et al. Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats[J].J Diabetes,2015,7(4):584-588.DOI:10.1111/1753-0407.12282.
[7] Nuche-Berenguer B,Moreno P,Portal-Nún～ez S,et al. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states[J].Regul Pept,2010,159(1-3):61-66.DOI:10.1016/j.regpep.2009.06.010.
[8] Hygum K,Starup-Linde J,Harsløf T,et al. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover-a systematic review and meta-analysis[J].Eur J Endocrinol,2017,176(3):R137-R157.DOI:10.1530/EJE-16-0652.
[9] Kim JY,Lee SK,Jo KJ,et al.Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes[J].Life Sci,2013,92(10):533-540.DOI:10.1016/j.lfs.2013.01.001.
[10] Pereira M,Jeyabalan J,Jørgensen CS,et al. Chronic administration of glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice[J].Bone,2015,81:459-467.DOI:10.1016/j.bone.2015.08.006.
[11] Eom YS,Gwon AR,Kwak KM,et al.Protective effects of vildagliptin against pioglitazone-induced bone loss in type 2 diabetic rats[J].PLoS One,2016,11(12):e0168569.DOI:10.1371/journal.pone.0168569.
[12] Meng J, Ma X, Wang N,et al. Activation of GLP-1 receptor promotes bone marrow stromal cell osteogenic differentiation through β-catenin[J]. Stem Cell Reports,2016,6(4):579-591.DOI:10.1016/j.stemcr.2016.02.002.
[13] Sanz C,Vázquez P,Blázquez C,et al. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow[J].Am J Physiol Endocrinol Metab,2010,298(3):E634-E643. DOI:10.1152/ajpendo.00460.2009.
[14] Lee HM,Joo BS,Lee CH,et al.Effect of glucagon-like peptide-1 on the differentiation of adipose-derived stem cells into osteoblasts and adipocytes[J].J Menopausal Med,2015,21(2):93-103.DOI:10.6118/jmm.2015.21.2.93.
[15] Yamagishi S.Comment on:Monami et al. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials[J]. Diabetes Care 2011; 34:2474-2476[J].Diabetes Care,2012,35(4):e33.DOI:10.2337/dc11-2561.
[16] Yamada C,Yamada Y,Tsukiyama K,et al.The murine glucagon-like peptide-1 receptor is essential for control of bone resorption[J].Endocrinology,2008,149(2):574-579.DOI:10.1210/en.2007-1292.
[17] Gier B,Butler PC,Lai CK,et al.Glucagon like peptide-1 receptor expression in the human thyroid gland[J].J Clin Endocrinol Metab,2012,97(1):121-131.DOI:10.1210/jc.2011-2407.
[18] Waser B,Blank A,Karamitopoulou E,et al.Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas[J].Mod Pathol,2015,28(3):391-402.DOI:10.1038/modpathol.2014.113.
[19] Nuche-Berenguer B,Moreno P,Esbrit P,et al.Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states[J].Calcif Tissue Int,2009,84(6):453-461.DOI:10.1007/s00223-009-9220-3.
[20] Nuche-Berenguer B,Lozano D,Gutiérrez-Rojas I,et al.GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia[J].J Endocrinol,2011,209(2):203-210.DOI:10.1530/JOE-11-0015.
[21] Mieczkowska A,Mansur S,Bouvard B,et al.Double incretin receptor knock-out(DIRKO)mice present with alterations of trabecular and cortical micromorphology and bone strength[J].Osteoporos Int,2015,26(1):209-218.DOI:10.1007/s00198-014-2845-8.
[22] Su B,Sheng H,Zhang M,et al.Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials[J].Endocrine,2015,48(1):107-115.DOI:10.1007/s12020-014-0361-4.
[23] Mabilleau G,Mieczkowska A,Chappard D.Use of glucagon-like peptide-1 receptor agonists and bone fractures: a meta-analysis of randomized clinical trials[J].J Diabetes,2014,6(3):260-266.DOI:10.1111/1753-0407.12102.
[24] Dombrowski S,Kostev K,Jacob L.Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data[J].Osteoporos Int,2017,28(8):2421-2428.DOI:10.1007/s00198-017-4051-y.
[25] Monami M,Dicembrini I,Antenore A,et al.Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials[J].Diabetes Care,2011,34(11):2474-2476.DOI:10.2337/dc11-1099.
[26] Fu J,Zhu J,Hao Y,et al. Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials[J].Sci Rep,2016,6:29104.DOI:10.1038/srep29104.DOI:10.1038/srep29104.
[27] Mamza J,Marlin C,Wang C,et al.DPP-4 inhibitor therapy and bone fractures in people with type 2 diabetes-a systematic review and meta-analysis[J].Diabetes Res Clin Pract,2016,116:288-298.DOI:10.1016/j.diabres.2016.04.029.
[28] Li R,Xu W,Luo S,et al.Effect of exenatide, insulin and pioglitazone on bone metabolism in patients with newly diagnosed type 2 diabetes[J].Acta Diabetol,2015,52(6):1083-1091.DOI:10.1007/s00592-015-0792-2.
相似文献/References:
[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(04):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(04):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(04):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[4]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(04):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[5]姚红,郗光霞,郭敏,等.胰高血糖素样肽-1及其受体在中枢神经系统的分布和功能[J].国际内分泌代谢杂志,2014,(01):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
Yao Hong*,Xi Guangxia,Guo Min,et al.The distributions and functions of glucagon like peptide-1 and its receptors in the central nervous system[J].International Journal of Endocrinology and Metabolism,2014,(04):36.[doi:10.3760/cma.j.issn.1673-4157.2014.01.010]
[6]黄婷婷,沈飞霞,谷雪梅.胰高血糖素样肽-1与骨骼肌葡萄糖代谢[J].国际内分泌代谢杂志,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
Huang Tingting,Shen Feixia,Gu Xuemei..Glucagon-like peptide-1 and glucose metabolism in the skeletal muscle[J].International Journal of Endocrinology and Metabolism,2014,(04):281.[doi:10.3760/cma.j.issn.1673-4157.2014.04.019]
[7]赵荷珺 洪天配.胰高血糖素样肽-1类药物与胰腺安全性[J].国际内分泌代谢杂志,2015,(05):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
Zhao Hejun*,Hong Tianpei..Glucagon-like peptide-1-based therapies and pancreatic safety[J].International Journal of Endocrinology and Metabolism,2015,(04):319.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.05.008]
[8]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性
血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(04):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[9]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白
与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(04):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[10]王涛,张洁,祁范范,等.不同糖耐量人群血清25(OH)D3水平
及与胰岛β细胞功能的关系[J].国际内分泌代谢杂志,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
Wang Tao*,Zhang Jie,Qi Fanfan,et al.Relationship between serum 25(OH)D3 level and islet β cell function in individuals with different glucose tolerance[J].International Journal of Endocrinology and Metabolism,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
[11]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(04):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[12]韩丽萍,陈莉明.GLP-1的神经保护作用[J].国际内分泌代谢杂志,2016,36(05):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
Han Liping,Chen Liming.Neuroprotective actions of glucagon-like peptide-1[J].International Journal of Endocrinology and Metabolism,2016,36(04):316.[doi:10.3760/cma.j.issn.1673-4157.2016.05.08]
[13]史雨清,杨昱,李宸,等.Tirzepatide:一种新型GLP-1/GIP双受体激动剂[J].国际内分泌代谢杂志,2021,41(06):645.[doi:10.3760/cma.j.cn121383-20200924-09046]
Shi Yuqing,Yang Yu,Li Chen,et al.Tirzepatide:a novel GLP-1/GIP dual receptor agonist[J].International Journal of Endocrinology and Metabolism,2021,41(04):645.[doi:10.3760/cma.j.cn121383-20200924-09046]